Absci Corporation · NASDAQ:ABSI
Absci — Corporate Update (May 2025)
41 slides from Absci's corporate update, May 13, 2025
Slide 1: Drug Creation Pipeline Program Updates May 2025
GENERATIVE AI ABSCI CORPORATION 2025 ALL RIGHTS RESERVED DRUG CREATION PIPELINE PROGRAM UPDATES MAY 2025
Slide 2: Disclaimers
2N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Disclaimers Forward-Looking Statements Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section
Slide 3: AI Pipeline
3N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . INFL. Bowel Disease / TL1A Androgenic Alopecia / PRLR Immuno-oncology / Undisclosed Additional Early Discovery Programs Target Lead ID Candidate ID IND-Enabling ABS-101
Slide 4: Absci's progress in Drug Creation
4N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 1 0 1 Phase 1 Program initiated in May 2025 • New preclinical data supporting superior immunogenicity profile • Phase 1 Interim data readout in 2H 2025 A B S - 2
Slide 5: Validated mechanism of action in large underserved market
5N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Validated mechanism of action in large underserved market A B S - 1 0 1 T L 1 A P O T E N T I A L R E L E V A N C E I N W I D E R A N G E O F A U T O I M M U N E I N D I
Slide 6: Potential best-in-class TL1A mAb designed using generative AI
6N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Potential best-in-class TL1A mAb designed using generative AI ABS-101 designed to achieve superior therapeutic properties and differentiation over first generation clini
Slide 7: Successful application of AI platform to generate high affinity variants
7N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Successful application of AI platform to generate high affinity variants A B S - 1 0 1 T L 1 A H I G H A F F I N I T Y m A b s W I T H P R E S E R V E D C R O S S - R E
Slide 8: AI-designed candidate with high affinity and superior potency
8N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . 1101001000 1 10 100 1000 Monom er Bind ing (pM) Tr im er B in di ng (p M ) No M onomer Bind ing H I G H A F F I N I T Y m A b s W I T H B I N D I N G T O B O T H T H E T
Slide 9: Internalization of mAb:TL1A complexes and immunogenicity assessment
9N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Internalization of mAb:TL1A complexes potentially contributes to immune activation and formation of ADA A B S - 1 0 1 T L 1 A | I M M U N O G E N I C I T Y A S S E S S M
Slide 10: NHP Pharmacokinetics & CMC data confirm competitive profile
10N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . NHP Pharmacokinetics & CMC data confirm compelling ABS-101 competitive profile A B S - 1 0 1 T L 1 A | N H P C O M P A R A T I V E P K 2-3x extended half-life in NHPs o
Slide 11: ABS-101 NHP data confirm sustained target engagement
11N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-101 NHP data confirm sustained prolonged targe engagement versus clinical competitors A B S - 1 0 1 T L 1 A | N H P C O M P A R A T I V E P D ! "! #! A! %! &! '! !(
Slide 12: AI-designed for potentially optimal therapeutic profile
12N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI-designed for potentially optimal therapeutic profile A B S - 1 0 1 T L 1 A A T T R I B U T E ABS - 1 0 1 M K - 7 2 4 0 ( M E R C K , P R O M E T H E U S ) R V T - 3
Slide 13: Phase 1 Clinical Trial Initiated in May 2025
13N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Phase 1 Clinical Trial Initiated in May 2025 A B S - 1 0 1 T L 1 A AI-designed Development Candidate ü High affinity ü High potency ü Long half-life ü Favorable manufac
Slide 14: Absci's progress in Drug Creation
14N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 1 0 1 Continued progress of TL1A asset with FiH in 1H 2025 • New preclinical data supporting superior immunogenicity profile • Phase 1 Interim data readout in 2
Slide 15: ABS-201 potential to unlock a new category of therapy in hair re-growth
15N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 has the potential to unlock a wholly new category of therapy in hair “re-growth” Significant unmet clinical need for androgenetic alopecia Large market: approxi
Slide 16: Underserved patient population looking for therapeutic innovation
16N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Underserved patient population looking for therapeutic innovation FEMALE ANDROGENETIC ALOPECIA ~30M women in the U.S. Only 1 FDA approved therapy for women ~50M men in
Slide 17: Patients and clinicians need better treatment options for hair re-growth
17N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Patients and clinicians need better treatment options for “hair re-growth” • Hair re-growth, not just slowing of hair loss • Safe • Minimal side effects • Durable effec
Slide 18: Potential best-in-class PRLR antibody for treating androgenic alopecia
18N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Potential best-in-class PRLR antibody for treating androgenic alopecia A B S - 2 0 1 P R L R AI-designed PRLR program for durable hair regrowth therapy addressing patie
Slide 19: PRLR inhibition as a safe innovative alternative
19N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . PRLR inhibition as a safe innovative alternative to current treatment options A B S - 2 0 1 P R L R | P R O P O S E D D I R E C T M O D E O F A C T I O N P r o p o s e
Slide 20: Prolactin impacts on organ-cultured human hair follicles
20N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Prolactin impacts on organ-cultured human hair follicles 1doi: 10.2353/ajpath.2006.050468 P r o l a c t i n - d r i v e s h a i r f o l l i c l e r e g r e s s i o n i
Slide 21: PRLR inhibition anticipated to be safe, supported by human genetics
21N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . PRLR inhibition anticipated to be safe & well tolerated as supported by human genetics A B S - 2 0 1 P R L R I. II. III. NV = Nonvariant ND = Not determined I. II. III.
Slide 22: Anti-PRLR mAb promotes and sustains long-term hair growth in NHP
22N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . TREATMENT WITH AN ANTI-PRLR MAB PROMOTES AND SUSTAINS LONG-TERM HAIR GROWTH IN NHP Hair density & thickness improved with short treatment duration in primate model of a
Slide 23: ABS-201 candidates are high affinity and potent binders
23N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 candidates are high affinity and potent binders A B S - 2 0 1 P R L R | I N V I T R O P R O F I L E PathHunter - in vitro PRLR reporter functional assay 10 - 3
Slide 24: ABS-201 shows superior efficacy vs 5% topical minoxidil
24N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model Administration: mAbs i.p. biweekly; Minoxidil topical daily Untreated (n=11) Isotype
Slide 25: 56 day interim NHP pharmacokinetic data for ABS-201
25N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . 56 day interim NHP pharmacokinetic data confirms ABS-201 is well positioned for AGA market A B S - 2 0 1 P R L R >3x extended half-life in NHPs compared to HMI-115 High
Slide 26: Straightforward path for ABS-201 clinical development
26N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Straightforward path for ABS-201 clinical development C L I N I C A L T R I A L S F O R H A I R T R E A T M E N T S A R E S T R A I G H T F O R W A R D • Ease of patien
Slide 27: Leading Scientific Advisory Board of Hair Experts
27N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leading Scientific Advisory Board of Hair Experts DR. ANTHONY ROSSI Memorial Sloan Kettering Cancer Center DR. CHESAHNA KINDRED Kindred Hair & Skin Center DR. MATT L. L
Slide 28: Absci's progress in Drug Creation
28N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 1 0 1 Continued progress of TL1A asset with FiH in 1H 2025 • New preclinical data supporting superior immunogenicity profile • Phase 1 Interim data readout in 2
Slide 29: Tertiary lymphoid structures and TLS-derived antibodies
29N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . The presence of TLS is associated with longer progression-free survival and better response to immune checkpoint inhibitors2,3. Rapidly growing evidence illustrates cor
Slide 30: Reverse Immunology platform identifies antigens targeted by TLS antibodies
30N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . LIGHT CHAINS HEAVY CHAINS Samples collected from patients with high expression of TLS markers Antibody expression Immunoglobulin reads from RNAseq data Target identific
Slide 31: ABS-301 rescues pro-inflammatory signaling
31N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 3 0 1 r e s c u e s p r o - i n f l a m m a t o r y s i g n a l i n g t h r o u g h i n h i b i t i o n o f i m m u n o s u p p r e s s i v e c y t o k i n e A
Slide 32: In vivo target validation: pathway activation drives anti-tumor response
32N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . In vivo Target Validation: Pathway Activation Drives Potent Anti-Tumor Response A B S - 3 0 1 Key Findings: Activation of the ABS-301–targeted pro-inflammatory pathway
Slide 33: Target expression suggests potential in squamous cell carcinomas
33N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Expression of ABS-301’s target suggests broad potential in squamous cell carcinomas A B S - 3 0 1 Distribution of ABS-301 target expression across squamous cell carcino
Slide 34: Expression in Lung Squamous Cell Carcinoma
34N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-301 | Expression in Lung Squamous Cell Carcinoma (LUSC): no change with treatment and strong negative correlation with CD8+ T cell infiltration In LUSC, univariate
Slide 35: ABS-301 broad potential in immuno-oncology
35N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-301 | Broad potential in immuno-oncology Based on literature and potential competitive molecules, the following indications could be of interest: *dependent on stag
Slide 36: Absci's progress in Drug Creation
36N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 1 0 1 Continued progress of TL1A asset with FiH in 1H 2025 • New preclinical data supporting superior immunogenicity profile • Phase 1 Interim data readout in 2
Slide 37: De novo AI model on HER2 discovers antibodies distinct from trastuzumab
37N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . • Hits with edit distance of up to 12 amino acids in HCDR3 region (13 aa, search space of 2013) were screened • Selected 50 hits with <10 nM affinity were expressed as
Slide 38: AI-designed antibodies enhance ADCC activity compared to trastuzumab
38N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Luciferase signal driven by NFAT transcription factor positively correlates to ADCC activation against JIMT-1 ABS-501, HER2 | AI-designed antibodies demonstrate measura
Slide 39: AI-designed antibodies suppress growth of HER2+ breast tumors
39N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-501, HER2 | AI-designed antibodies suppress growth of trastuzumab-sensitive & resistant HER2+ breast tumors Partial Critical Not critical Trastuzumab WT Variant 1 V
Slide 40: AI-designed antibodies create opportunities to address unmet medical need
40N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-501, HER2 | AI-designed antibodies create opportunities to address unmet medical need Modality switch or combination opportunities under consideration to address un
Slide 41: Better biologics for patients, faster
Better biologics for patients, faster 41N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D .